Market Performance - The market experienced a correction last week, with the Shanghai Composite Index down 0.94% and the Shenzhen Component Index down 1.58% [1] - The China Securities Index reported a decline of 1.64%, closing at 1712.78 points [1] Strong Performers - Several constituent stocks of the brand index rose against the market trend, with Zhongji Xuchuang up 13.72%, and Ecovacs up 11.07% [1] - Other notable gainers included Hengrui Medicine and Tigermed, which rose by 8.71% and 8.08% respectively [1] Year-to-Date Performance - Year-to-date, WuXi AppTec has surged by 72.63%, leading the gains, followed by Zhongji Xuchuang at 71.22% and Ecovacs at 68.82% [2] - A number of stocks, including Hengrui Medicine and Shanghai Jahwa, have increased by over 30% [2] Market Outlook - Short-term market conditions are expected to remain volatile, with potential profit-taking leading to adjustments in popular sectors [2][3] - Despite recent gains, many sectors are still considered undervalued, indicating limited overall market risk [2] Economic Context - The recent market adjustment may be attributed to weakening market drivers and heightened emotional and trading influences [3] - However, the domestic economy is on a recovery path, and ongoing capital market reforms are expected to support a positive medium-term outlook [3]

Core Viewpoint - The focus is on identifying and investing in pharmaceutical advanced manufacturing companies that have global competitive advantages and are poised for growth due to market integration and emerging demand [1][4]. Group 1: Investment Philosophy - The investment approach emphasizes steady performance and the importance of companies that can deliver profits, rather than speculative investments [2][3]. - The strategy involves identifying companies that have completed their first growth curve and are in a dormant phase, which may present good buying opportunities [2][3]. Group 2: Industry Insights - The pharmaceutical manufacturing sector is unique due to high compliance costs and registration barriers, which create a competitive moat for leading companies [4]. - The raw material drug industry is expected to see continuous opportunities due to the lifecycle of drugs and the ongoing demand for new products [5]. Group 3: Market Trends - Companies in the raw material drug, device consumables, and CDMO sectors are anticipated to experience operational efficiency improvements and profit surges as new orders and clients emerge [5]. - The innovative drug sector is currently facing challenges in profit realization, with significant uncertainties regarding large-scale profit generation [6]. Group 4: Future Outlook - There is a belief that the innovative drug industry will continue to develop, presenting valuable investment opportunities in the future [6]. - The potential for significant growth in the pharmaceutical manufacturing sector is highlighted, particularly for companies that can adapt to new market demands and integrate effectively [4][5].

Core Viewpoint - In 2025, equity funds experienced a remarkable turnaround, with the top 30 actively managed equity funds achieving returns exceeding 50%, highlighting the success of Penghua Fund's long-term focus on fundamental investment and industry trends [1] Performance Leadership: Multi-Dimensional Data Validation - Penghua's equity product matrix demonstrated a "blooming" performance, with 26 funds ranking in the top 20% of their categories over the past year, including several champions in niche sectors [2] - The Penghua Innovation Growth One-Year Holding Mixed Fund ranked in the top 1% (21/1804) in the competitive equity fund sector, with five products entering the top 6% [2][3] - Notable rankings include: - Penghua Medical Technology Stock Fund: 1/44 in the medical health sector - Penghua Carbon Neutral Theme Mixed Fund: 1/32 in low-carbon equity - Penghua New Energy Vehicle Theme Mixed Fund: 2/16 in automotive sector [2] Recent Performance Metrics - Ten equity funds reported over 20% net value growth in the past six months, with six funds achieving excess returns of over 15 percentage points relative to their benchmarks [4] - Ten equity funds also recorded over 30% net value growth in the past year, with the Penghua Carbon Neutral Theme A Fund achieving a return of 84.90% [5] Investment Strategy and Team Expertise - Penghua Fund's Alpha team employs a diversified investment style, covering a wide range of market opportunities, with different fund managers generating excess returns in their respective fields [6] - Key fund managers include: - Yan Siqian, focusing on technology investments, particularly in the new energy vehicle sector [7] - Jin Xiaofei, specializing in innovative pharmaceuticals and AI healthcare [8] - Wang Lu, an expert in the semiconductor industry [10] - The investment strategies are characterized by a blend of fundamental analysis and quantitative tools, allowing for a comprehensive approach to investment [31] Conclusion: Sustainable Growth Confidence - The performance surge in 2025 is attributed to a robust research system and a well-structured talent pipeline, enabling Penghua Fund to consistently deliver replicable and sustainable excess returns [32]